SLC6A3 and Alzheimer disease: Given the evolution of the syndrome, to further differentiate between PCA/AD and DLB presenting as PCA, a dopamine transporter imaging (DAT-SPECT) was obtained confirming dopaminergic neurodegeneration leading to a final diagnosis of DLB with comorbid AD (or mixed DLB/AD; panel F).